Abstract
Previously, studies of the endocrine pancreatic β-cell were mainly performed ex vivo by morphological means. This data supported the analyis of pathophysiological changes in the pancreatic islet during insults such as diabetes mellitus. Metabolic testing of the pancreatic islet by assaying hormone parameters such as plasma insulin or C-peptide combined with more or less sophisticated calculations allowed conclusions about states of insulin resistance or secretory failure. It also allowed certain correlations of endocrine function with β-cell mass. Today, with firmer pathophysiological concepts about β-cell failure, modern protocols of islet transplantation, and drugs on the market coming with promises of preservation or even expansion of β-cell mass in diabetes mellitus it has become very attractive to search for tools measuring β-cell mass, if possible even repeatedly in the same organism in vivo. From a clinical point of view, the potential of pancreatic β-cell mass imaging technologies is looked upon with high expectations. Methodologically, the decisive question is whether it is likely that future β-cell imaging will provide significant advantages over the metabolic methods already in hand. With new in vivo tools, studies of β-cell mass and function may offer even new approaches stratifying patients to anti-diabetic therapies.
Keywords: diabetes mellitus, C-peptide, OGTT, pancreatic β-cell
Current Pharmaceutical Design
Title: What are the Potential Benefits of Clinical β-Cell Imaging in Diabetes Mellitus?
Volume: 16 Issue: 14
Author(s): Burkhard Goke
Affiliation:
Keywords: diabetes mellitus, C-peptide, OGTT, pancreatic β-cell
Abstract: Previously, studies of the endocrine pancreatic β-cell were mainly performed ex vivo by morphological means. This data supported the analyis of pathophysiological changes in the pancreatic islet during insults such as diabetes mellitus. Metabolic testing of the pancreatic islet by assaying hormone parameters such as plasma insulin or C-peptide combined with more or less sophisticated calculations allowed conclusions about states of insulin resistance or secretory failure. It also allowed certain correlations of endocrine function with β-cell mass. Today, with firmer pathophysiological concepts about β-cell failure, modern protocols of islet transplantation, and drugs on the market coming with promises of preservation or even expansion of β-cell mass in diabetes mellitus it has become very attractive to search for tools measuring β-cell mass, if possible even repeatedly in the same organism in vivo. From a clinical point of view, the potential of pancreatic β-cell mass imaging technologies is looked upon with high expectations. Methodologically, the decisive question is whether it is likely that future β-cell imaging will provide significant advantages over the metabolic methods already in hand. With new in vivo tools, studies of β-cell mass and function may offer even new approaches stratifying patients to anti-diabetic therapies.
Export Options
About this article
Cite this article as:
Goke Burkhard, What are the Potential Benefits of Clinical β-Cell Imaging in Diabetes Mellitus?, Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164081
DOI https://dx.doi.org/10.2174/138161210791164081 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autophagy to the Rescue
Current Neurovascular Research Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Nephron Number Reduction and Low Birth Weight: A Concern for the Paediatrician and Beyond
Current Pediatric Reviews On the Diversity of Oxidative Bioactivation Reactions on Nitrogen- Containing Xenobiotics
Current Drug Metabolism Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Role of Mammalian Target of Rapamycin in Atherosclerosis
Current Molecular Medicine Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
Current Vascular Pharmacology The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Clozapine Safety, 40 Years Later
Current Drug Safety The Molecular Targets of Swertiamarin and its Derivatives Confer Anti- Diabetic and Anti-Hyperlipidemic Effects
Current Drug Targets Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke
Current Neurovascular Research Antidyslipidemic and Antioxidant Activities of <i>Matricaria pubescens</i> (Desf.) Shultz. in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Preface
Current Molecular Medicine Astrocytic 5-HT2B Receptor as in vitro and in vivo Target of SSRIs
Recent Patents on CNS Drug Discovery (Discontinued) Hydrogen Sulphide: Biopharmacological Roles in the Cardiovascular System and Pharmaceutical Perspectives
Current Medicinal Chemistry